Effects of MEDI0382, a glucagon-like peptide 1/glucagon receptor dual agonist, on pancreatic and incretin hormones

被引：0
|
作者：
Jermutus, L. [1 ]
Tsai, L. -F. [2 ]
Robertson, D. [1 ]
Petrone, M. [1 ]
Rondinone, C. [2 ]
Boaz, H. [2 ]
Ambery, P. [1 ]
Parker, V. [1 ]
机构：
[1] MedImmune, Cambridge, England
[2] MedImmune, Gaithersburg, MD USA
来源：
DIABETOLOGIA | 2018年 / 61卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
778
引用
收藏
页码：S382 / S382
页数：1
相关论文
共 50 条
  • [41] Measurement of the incretin hormones: glucagon-like peptide-1 and glucose-dependent insulinotropic peptide
    Kuhre, Rune Ehrenreich
    Albrechtsen, Nicolai Jacob Wewer
    Hartmann, Bolette
    Deacon, Carolyn F.
    Hoist, Jens Juul
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2015, 29 (03) : 445 - 450
  • [42] Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes
    D'Alessio, DA
    Vahl, TP
    AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2004, 286 (06): : E882 - E890
  • [43] Receptor occupancy of dual glucagon-like peptide 1/glucagon receptor agonist SAR425899 in individuals with type 2 diabetes
    Olof Eriksson
    Torsten Haack
    Youssef Hijazi
    Lenore Teichert
    Veronique Tavernier
    Iina Laitinen
    Jan Erik Berglund
    Gunnar Antoni
    Irina Velikyan
    Lars Johansson
    Stefan Pierrou
    Michael Wagner
    Joachim Tillner
    Scientific Reports, 10
  • [44] Receptor occupancy of dual glucagon-like peptide 1/glucagon receptor agonist SAR425899 in individuals with type 2 diabetes
    Eriksson, Olof
    Haack, Torsten
    Hijazi, Youssef
    Teichert, Lenore
    Tavernier, Veronique
    Laitinen, Iina
    Berglund, Jan Erik
    Antoni, Gunnar
    Velikyan, Irina
    Johansson, Lars
    Pierrou, Stefan
    Wagner, Michael
    Tillner, Joachim
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [45] Antiobesity therapeutics with complementary dual-agonist activities at glucagon and glucagon-like peptide 1 receptors
    Park, Bong Gyu
    Kim, Gyeong Min
    Lee, Hye-Jin
    Ryu, Jae Ha
    Kim, Dong-Hoon
    Seong, Jae-Young
    Kim, Soojeong
    Park, Zee-Yong
    Kim, Young-Joon
    Lee, Jaemin
    Kim, Jae Il
    DIABETES OBESITY & METABOLISM, 2022, 24 (01): : 50 - 60
  • [46] A novel glucagon-like peptide-1/glucagon receptor dual agonist exhibits weight-lowering and diabetes-protective effects
    Zhou, Jie
    Cai, Xingguang
    Huang, Xun
    Dai, Yuxuan
    Sun, Lidan
    Zhang, Bo
    Yang, Bo
    Lin, Haiyan
    Huang, Wenlong
    Qian, Hai
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, 138 : 1158 - 1169
  • [47] Significance of expression of glucagon-like peptide 1 receptor in pancreatic cancer
    Cases, Ana Ines
    Ohtsuka, Takao
    Kimura, Hidey
    Zheng, Biao
    Shindo, Koji
    Oda, Yoshinao
    Mizumoto, Kazuhiro
    Nakamura, Masafumi
    Tanaka, Masao
    ONCOLOGY REPORTS, 2015, 34 (04) : 1717 - 1725
  • [48] Insulin receptor signaling and glucagon-like peptide 1 effects on pancreatic beta cells
    Caporarello, Nunzia
    Parrino, Cristina
    Trischitta, Vincenzo
    Frittitta, Lucia
    PLOS ONE, 2017, 12 (08):
  • [49] Design of a long acting peptide functioning as both a glucagon-like peptide-1 receptor agonist and a glucagon receptor antagonist
    Pan, CQ
    Buxton, JM
    Yung, SL
    Tom, I
    Yang, L
    Chen, HX
    MacDougall, M
    Bell, A
    Claus, TH
    Clairmont, KB
    Whelan, JP
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (18) : 12506 - 12515
  • [50] Association of glucagon-like peptide-1 receptor-targeted imaging probe with in vivo glucagon-like peptide-1 receptor agonist glucose-lowering effects
    Murakami, Takaaki
    Fujimoto, Hiroyuki
    Fujita, Naotaka
    Hamamatsu, Keita
    Yabe, Daisuke
    Inagaki, Nobuya
    JOURNAL OF DIABETES INVESTIGATION, 2020, 11 (06) : 1448 - 1456
12345